OncoTargets and Therapy
Volume 15, 2022 - Issue
Open access
104
Views
1
CrossRef citations to date
0
Altmetric
Case Report
FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
Chen HongDepartment of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China
https://orcid.org/0000-0002-9292-5902View further author information
Jianping WeiDepartment of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of ChinaView further author information
, Tao ZhouDepartment of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of ChinaView further author information
, Xia WangDepartment of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China
https://orcid.org/0000-0002-6986-0979View further author information
Jing CaiDepartment of Oncology, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of ChinaCorrespondence[email protected]
View further author information
View further author information
Pages 651-657
|
Published online: 10 Jun 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.